BioXcel Therapeutics Current Cash

BioXcel Therapeutics (BTAI) currently reports a current cash of $13M as of June 2026. That compares with $17M in the prior-year period — down 26.3% year over year. Use the charts on this page to explore BioXcel Therapeutics's current cash history and peer comparisons.

BioXcel Therapeutics's current cash decreased from $17M to $13M — a 26.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioXcel Therapeutics reported $13M in current cash as of June 2026. That compares with $17M in the prior-year period — down 26.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $13M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BioXcel Therapeutics, and consider following BTAI for alerts when major investors trade the stock.

BioXcel Therapeutics is classified in the Healthcare sector. On current cash, it currently shows $13M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BTAI with unrelated industries.